|
1
|
Eng C: PTEN: One gene, many syndromes. Hum
Mutat. 22:183–98. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tan MH, Mester JL, Ngeow J, Rybicki LA,
Orloff MS and Eng C: Lifetime cancer risks in individuals with
germline PTEN mutations. Clin Cancer Res. 18:400–407. 2012.
View Article : Google Scholar :
|
|
3
|
Schmid GL, Kässner F, Uhlig HH, Körner A,
Kratzsch J, Händel N, Zepp FP, Kowalzik F, Laner A, Starke S, et
al: Sirolimus treatment of severe PTEN hamartoma tumor syndrome:
Case report and in vitro studies. Pediatr Res. 75:527–534. 2014.
View Article : Google Scholar
|
|
4
|
Hollander MC, Blumenthal GM and Dennis PA:
PTEN loss in the continuum of common cancers, rare syndromes and
mouse models. Nat Rev Cancer. 11:289–301. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mauro VF and MacDonald JL: Simvastatin: A
review of its pharmacology and clinical use. DICP. 25:257–64. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Desai CS, Martin SS and Blumenthal RS:
Non-cardiovascular effects associated with statins. BMJ.
349:g37432014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhong S, Zhang X, Chen L, Ma T, Tang J and
Zhao J: Statin use and mortality in cancer patients: Systematic
review and meta-analysis of observational studies. Cancer Treat
Rev. 41:554–567. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nielsen SF, Nordestgaard BG and Bojesen
SE: Statin use and reduced cancer-related mortality. N Engl J Med.
367:1792–1802. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Campbell MJ, Esserman LJ, Zhou Y,
Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx
C, et al: Breast cancer growth prevention by statins. Cancer Res.
66:8707–8714. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fang Z, Tang Y, Fang J, Zhou Z, Xing Z,
Guo Z, Guo X, Wang W, Jiao W, Xu Z and Liu Z: Simvastatin inhibits
renal cancer cell growth and metastasis via AKT/mTOR, ERK and
JAK2/STAT3 pathway. PLoS One. 8:e628232013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang T, Seah S, Loh X, Chan CW, Hartman M,
Goh BC and Lee SC: Simvastatin-induced breast cancer cell death and
deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by
metabolic products of the mevalonate pathway. Oncotarget.
7:2532–2544. 2016.
|
|
12
|
Chen YQ, Zhao LY, Zhang WZ and Li T:
Simvastatin reverses cardiomyocyte hypertrophy via the upregulation
of phosphatase and tensin homolog expression. Exp Ther Med.
10:797–803. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ghosh-Choudhury N, Mandal CC,
Ghosh-Choudhury N and Ghosh Choudhury G: Simvastatin induces
derepression of PTEN expression via NFkappaB to inhibit breast
cancer cell growth. Cell Signal. 22:749–58. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Self TH and Akins D: Dramatic reduction in
lipoma associated with statin therapy. J Am Acad Dermatol. 58(2
Suppl): S30–S31. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wilhelm F, Kässner F, Schmid G, Kratzsch
J, Laner A, Wabitsch M, Körner A, Kiess W and Garten A:
Phosphatidylinositol 3-kinase (PI3K) signalling regulates
insulin-like-growth factor binding protein-2 (IGFBP-2) production
in human adipocytes. Growth Horm IGF Res. 25:115–120. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fischer-Posovszky P, Newell FS, Wabitsch M
and Tornqvist HE: Human SGBS cells-a unique tool for studies of
human fat cell biology. Obes Facts. 1:184–189. 2008. View Article : Google Scholar
|
|
17
|
Wabitsch M, Brenner RE, Melzner I, Braun
M, Möller P, Heinze E, Debatin KM and Hauner H: Characterization of
a human preadipocyte cell strain with high capacity for adipose
differentiation. Int J Obes Relat Metab Disord. 25:8–15. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bernhard F, Landgraf K, Klöting N,
Berthold A, Büttner P, Friebe D, Kiess W, Kovacs P, Blüher M and
Körner A: Functional relevance of genes implicated by obesity
genome-wide association study signals for human adipocyte biology.
Diabetologia. 56:311–322. 2013. View Article : Google Scholar
|
|
19
|
Tu J, Li W, Zhang Y, Wu X, Song Y, Kang L,
Liu W, Wang K, Li S, Hua W and Yang C: Simvastatin inhibits
IL-1β-induced apoptosis and extracellular matrix degradation by
suppressing the NF-κB and MAPK pathways in nucleus pulposus cells.
Inflammation. 40:725–734. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Spampanato C, De Maria S, Sarnataro M,
Giordano E, Zanfardino M, Baiano S, Cartenì M and Morelli F:
Simvastatin inhibits cancer cell growth by inducing apoptosis
correlated to activation of Bax and downregulation of BCL-2 gene
expression. Int J Oncol. 40:935–941. 2012. View Article : Google Scholar
|
|
21
|
Åberg M, Wickström M and Siegbahn A:
Simvastatin induces apoptosis in human breast cancer cells in a
NFκB-dependent manner and abolishes the anti-apoptotic signaling of
TF/FVIIa and TF/FVIIa/FXa. Thromb Res. 122:191–202. 2008.
View Article : Google Scholar
|
|
22
|
Pi WF, Guo XJ, Su LP and Xu WG:
Troglitazone upregulates PTEN expression and induces the apoptosis
of pulmonary artery smooth muscle cells under hypoxic conditions.
Int J Mol Med. 32:1101–1109. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Farrow B and Evers BM: Activation of
PPARgamma increases PTEN expression in pancreatic cancer cells.
Biochem Biophys Res Commun. 301:50–53. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vella V, Nicolosi ML, Giuliano S, Bellomo
M, Belfiore A and Malaguarnera R: PPAR-γ agonists as antineoplastic
agents in cancers with dysregulated IGF axis. Front Endocrinol
(Lausanne). 8:312017.
|
|
25
|
Wang G, Cao R, Wang Y, Qian G, Dan HC,
Jiang W, Ju L, Wu M, Xiao Y and Wang X: Simvastatin induces cell
cycle arrest and inhibits proliferation of bladder cancer cells via
PPARγ signalling pathway. Sci Rep. 6:357832016. View Article : Google Scholar
|
|
26
|
Marsh DJ, Trahair TN, Martin JL, Chee WY,
Walker J, Kirk EP, Baxter RC and Marshall GM: Rapamycin treatment
for a child with germline PTEN mutation. Nat Clin Pract Oncol.
5:357–361. 2008.PubMed/NCBI
|
|
27
|
Iacobas I, Burrows PE, Adams DM, Sutton
VR, Hollier LH and Chintagumpala MM: Oral rapamycin in the
treatment of patients with hamartoma syndromes and PTEN mutation.
Pediatr Blood Cancer. 57:321–323. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Heindl M, Händel N, Ngeow J, Kionke J,
Wittekind C, Kamprad M, Rensing-Ehl A, Ehl S, Reifenberger J,
Loddenkemper C, et al: Autoimmunity, intestinal lymphoid
hyperplasia, and defects in mucosal B-cell homeostasis in patients
with PTEN hamartoma tumor syndrome. Gastroenterology.
142:1093–1096.e6. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Relja B, Meder F, Wilhelm K, Henrich D,
Marzi I and Lehnert M: Simvastatin inhibits cell growth and induces
apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int
J Mol Med. 26:735–741. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liang Z, Li W, Liu J, Li J, He F, Jiang Y,
Yang L, Li P, Wang B, Wang Y, et al: Simvastatin suppresses the DNA
replication licensing factor MCM7 and inhibits the growth of
tamoxifen-resistant breast cancer cells. Sci Rep. 7:417762017.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang ST, Ho HJ, Lin JT, Shieh JJ and Wu
CY: Simvastatin-induced cell cycle arrest through inhibition of
STAT3/SKP2 axis and activation of AMPK to promote 27 and 21
accumulation in hepatocellular carcinoma cells. Cell Death Dis.
8:e26262017. View Article : Google Scholar
|
|
32
|
Cafforio P, Dammacco F, Gernone A and
Silvestris F: Statins activate the mitochondrial pathway of
apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis.
26:883–891. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Denoyelle C, Vasse M, Körner M, Mishal Z,
Ganné F, Vannier JP, Soria J and Soria C: Cerivastatin, an
inhibitor of HMG-CoA reductase, inhibits the signaling pathways
involved in the invasiveness and metastatic properties of highly
invasive breast cancer cell lines: An in vitro study.
Carcinogenesis. 22:1139–1148. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen HH, Händel N, Ngeow J, Muller J, Hühn
M, Yang HT, Heindl M, Berbers RM, Hegazy AN, Kionke J, et al:
Immune dysregulation in patients with PTEN hamartoma tumor
syndrome: Analysis of FOXP3 regulatory T cells. J Allergy Clin
Immunol. 139:607–620.e15. 2017. View Article : Google Scholar
|
|
35
|
Lin CF, Young KC, Bai CH, Yu BC, Ma CT,
Chien YC, Chiang CL, Liao CS, Lai HW and Tsao CW: Rosiglitazone
regulates anti-inflammation and growth inhibition via PTEN. Biomed
Res Int. 2014:7879242014.PubMed/NCBI
|
|
36
|
Aiello A, Pandini G, Frasca F, Conte E,
Murabito A, Sacco A, Genua M, Vigneri R and Belfiore A: Peroxisomal
proliferator-activated receptor-gamma agonists induce partial
reversion of epithelial-mesenchymal transition in anaplastic
thyroid cancer cells. Endocrinology. 147:4463–4475. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Han S and Roman J: Rosiglitazone
suppresses human lung carcinoma cell growth through
PPARgamma-dependent and PPARgamma-independent signal pathways. Mol
Cancer Ther. 5:430–437. 2006. View Article : Google Scholar
|
|
38
|
Zhuang L, Kim J, Adam RM, Solomon KR and
Freeman MR: Cholesterol targeting alters lipid raft composition and
cell survival in prostate cancer cells and xenografts. J Clin
Invest. 115:959–968. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Khan T, Hamilton MP, Mundy DI, Chua SC and
Scherer PE: Impact of simvastatin on adipose tissue: Pleiotropic
effects in vivo. Endocrinology. 150:5262–5272. 2009. View Article : Google Scholar : PubMed/NCBI
|
